Headache

Calix Releases Cloud and Network Advancements for the Broadband Industry’s Only End-to-End Platform, Further Simplifying Operations for Broadband Providers

Retrieved on: 
Wednesday, February 21, 2024

Calix, Inc. (NYSE: CALX) today announced enhancements to the Calix Broadband Platform that further enable broadband service providers (BSPs) to simplify their operations and run incredibly efficient broadband businesses.

Key Points: 
  • Calix, Inc. (NYSE: CALX) today announced enhancements to the Calix Broadband Platform that further enable broadband service providers (BSPs) to simplify their operations and run incredibly efficient broadband businesses.
  • Enhancements to Calix Cloud enable operations teams to prioritize critical issues with improved outage detection , deeper insights, and customized, real-time alerts.
  • “The Calix Platform has fundamentally changed how our team operates,” said Josh Rice, network operations center supervisor at Tipmont.
  • Improvements to Calix Cloud give BSPs better visibility into the network before they act—reducing avoidable disruptions and enabling the adoption of a proactive mindset.

European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Monday, February 19, 2024

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
  • “For the 2.6 million people in Europe living with UC, the unpredictable physical, mental, and emotional impacts of the condition can be debilitating.
  • This authorization follows the recommendation for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2023.
  • Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of VELSIPITY.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
Friday, March 8, 2024

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Chairman of Avia Solutions Group Gediminas Ziemelis: 3 key trends in ACMI leasing as we enter 2024

Retrieved on: 
Friday, March 8, 2024

DUBLIN, March 8, 2024 /PRNewswire/ -- Gediminas Ziemelis, Chairman of Avia Solutions Group; the world's largest ACMI provider gave his insight for 2024 on aviation and how ACMI can create opportunity.

Key Points: 
  • DUBLIN, March 8, 2024 /PRNewswire/ -- Gediminas Ziemelis, Chairman of Avia Solutions Group; the world's largest ACMI provider gave his insight for 2024 on aviation and how ACMI can create opportunity.
  • Advances in automation and robotization also continue to show promising potential in terms of accelerating production and optimizing maintenance.
  • Labor shortages, financial limitations, supply-side issues, and the ongoing challenge of managing seasonality are all potential obstacles in airlines' quest for growth.
  • He spoke about the key trends related to these challenges, sharing some insights on how ACMI can help airlines to handle them.

Chairman of Avia Solutions Group Gediminas Ziemelis: 3 key trends in ACMI leasing as we enter 2024

Retrieved on: 
Friday, March 8, 2024

DUBLIN, March 8, 2024 /PRNewswire/ -- Gediminas Ziemelis, Chairman of Avia Solutions Group; the world's largest ACMI provider gave his insight for 2024 on aviation and how ACMI can create opportunity.

Key Points: 
  • DUBLIN, March 8, 2024 /PRNewswire/ -- Gediminas Ziemelis, Chairman of Avia Solutions Group; the world's largest ACMI provider gave his insight for 2024 on aviation and how ACMI can create opportunity.
  • Advances in automation and robotization also continue to show promising potential in terms of accelerating production and optimizing maintenance.
  • Labor shortages, financial limitations, supply-side issues, and the ongoing challenge of managing seasonality are all potential obstacles in airlines' quest for growth.
  • He spoke about the key trends related to these challenges, sharing some insights on how ACMI can help airlines to handle them.

Does Iron Accumulate in Brain After Concussions?

Retrieved on: 
Thursday, March 7, 2024

The study involved 60 people who had post-traumatic headache due to mild traumatic brain injury, or concussion.

Key Points: 
  • The study involved 60 people who had post-traumatic headache due to mild traumatic brain injury, or concussion.
  • The people with mild traumatic brain injuries were matched with 60 people who had not had concussions or post-traumatic headache.
  • All the participants had brain scans to look at iron levels in various areas of the brain, using an indirect measure for iron burden.
  • "Previous studies have shown that iron accumulation can affect how areas of the brain interact with each other," Nikolova said.

Tripleseat Solves The Large Party Reservation Problem for Restaurants and Their Guests

Retrieved on: 
Wednesday, March 6, 2024

CONCORD, Mass., March 6, 2024 /PRNewswire-PRWeb/ -- Tripleseat, the leading innovator in cloud-based sales and event management software for restaurants and hotels, launches a one-of-a-kind reservation solution to help consumers and restaurants reserve tables for large parties.

Key Points: 
  • Tripleseat launches Large Party Reservations, a one-of-a-kind solution to help consumers and restaurants reserve tables for large parties.
  • "The Large Party Reservations product solves a big problem for restaurants and addresses the needs of consumers by providing them with an easy and quick reservation capability," says Jonathan Morse, CEO of Tripleseat.
  • Built on the TripleseatDirect platform, the new Large Party Reservations solution caters to large party reservations typically between 6-15 people.
  • "The Large Party Reservations product solves a big problem for restaurants and addresses the needs of consumers by providing them with an easy and quick reservation capability."

Neurolenses Demonstrate Headache Relief in New Study

Retrieved on: 
Tuesday, March 5, 2024

DALLAS, March 5, 2024 /PRNewswire/ -- Neurolens, a company commercializing innovative solutions to provide effortless vision, announced today the results of a double-masked, crossover peer-reviewed publication demonstrating that Neurolenses provide significant relief from headaches. In this multi-site study (10 optometry practices, 195 patients), Neurolenses demonstrated a statistically significant level of impact based on the widely used and validated Headache Impact Test, or HIT-6*. These results were peer-reviewed and published by Translational Vision Science & Technology, a highly regarded medical journal published by the Association of Research in Vision and Ophthalmology (ARVO). "This is a landmark moment, not just for Neurolens, but for the entire vision industry," said Davis Corley, Neurolens CEO. "Neurolens is built on a clinical foundation, and we are pleased that a solution as simple and elegant as contoured prism lenses could expand the benefits of the annual eye exam. This study just reinforces what we already know: Neurolenses can change lives."

Key Points: 
  • A double-masked, randomized, cross-over clinical study shows that patients wearing Neurolenses had improved scores on a validated headache questionnaire.
  • DALLAS, March 5, 2024 /PRNewswire/ -- Neurolens, a company commercializing innovative solutions to provide effortless vision, announced today the results of a double-masked, crossover peer-reviewed publication demonstrating that Neurolenses provide significant relief from headaches.
  • In this multi-site study (10 optometry practices, 195 patients), Neurolenses demonstrated a statistically significant level of impact based on the widely used and validated Headache Impact Test, or HIT-6*.
  • This study just reinforces what we already know: Neurolenses can change lives."

6th Annual Crypto Tax Q&A Published by BitIRA

Retrieved on: 
Tuesday, March 5, 2024

BURBANK, Calif., March 5, 2024 /PRNewswire/ -- BitIRA – pioneer of the first insured cold storage solution for cryptocurrency retirement accounts – published its sixth annual Crypto Tax Q&A this week.

Key Points: 
  • BURBANK, Calif., March 5, 2024 /PRNewswire/ -- BitIRA – pioneer of the first insured cold storage solution for cryptocurrency retirement accounts – published its sixth annual Crypto Tax Q&A this week.
  • Each year, BitIRA polls crypto investors for tax questions and provides answers from leading cryptocurrency tax experts.
  • Specific topics covered in the crypto tax FAQ include:
    Among other tax related content, BitIRA also has an extensive page on crypto taxes , a directory of CPA advisors from around the country who are knowledgeable of crypto taxes, and an exclusive guide on crypto taxes.
  • "If you're tired of crypto tax questions, I heartily recommend a crypto IRA ," Warner said.